Original Research Prim Care Companion CNS Disord June 2020

Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study

PCC CNS Disord 2020;22(4):10.4088/PCC.19m02578

Full Article Read the complete peer-reviewed article in Prim Care Companion CNS Disord. Clinical Summary Patients with subthreshold or mild-to-moderate depressive symptoms are common in primary care, yet standard antidepressants offer limited benefit when baseline severity is low. This study tests a once-daily combination of SAMe and Lactobacillus plantarum HEAL9 in that clinically relevant gap, with early symptom change and short-term tolerability as the main practical questions. FAQ What did this randomized trial find about SAMe plus Lactobacillus plantarum HEAL9 for mild-to-moderate depressive symptoms?

Key Takeaways The intervention was tested in a primary care population with recurrent mild-to-moderate depressive disorders defined by ICD-10/F33 criteria and a baseline Z-SDS raw score between 41 and 55, which helps clarify that the findings apply to subthreshold to mild depressive presentations rather than severe major depressive disorder. Clinical Guide How can clinicians implement the studied SAMe plus Lactobacillus plantarum HEAL9 regimen for adults with subthreshold or mild-to-moderate depressive symptoms?